These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18685574)

  • 1. Bisphosphonate nephrotoxicity.
    Perazella MA; Markowitz GS
    Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
    Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
    Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease.
    Bergner R; Diel IJ; Henrich D; Hoffmann M; Uppenkamp M
    Onkologie; 2006 Nov; 29(11):534-40. PubMed ID: 17068390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal complications from bisphosphonate treatment.
    Hirschberg R
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):342-7. PubMed ID: 22710581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kidney and bisphosphonates.
    Miller PD
    Bone; 2011 Jul; 49(1):77-81. PubMed ID: 21232648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
    Markowitz GS; Appel GB; Fine PL; Fenves AZ; Loon NR; Jagannath S; Kuhn JA; Dratch AD; D'Agati VD
    J Am Soc Nephrol; 2001 Jun; 12(6):1164-1172. PubMed ID: 11373339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocyte Disease Following Treatment with Intravenous Ibandronate in an Older Patient.
    Chung YR; Lee HS; Lee DY; Lee SH; Jeong JS; Kim B
    Ann Geriatr Med Res; 2024 Jun; 28(2):228-230. PubMed ID: 38383148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management strategies for hypercalcemia.
    Pecherstorfer M; Brenner K; Zojer N
    Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.
    Jia N; Cormack FC; Xie B; Shiue Z; Najafian B; Gralow JR
    BMC Cancer; 2015 Jul; 15():535. PubMed ID: 26197890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
    Nagahama M; Sica DA
    Am J Med Sci; 2009 Sep; 338(3):225-8. PubMed ID: 19581797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
    Jotterand V; Moll S; Martin PY; Saudan P
    Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
    Banerjee D; Asif A; Striker L; Preston RA; Bourgoignie JJ; Roth D
    Am J Kidney Dis; 2003 May; 41(5):E18. PubMed ID: 12778436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
    Bergner R; Siegrist B; Gretz N; Pohlmeyer-Esch G; Kränzlin B
    Pharmacol Res; 2015 Sep; 99():16-22. PubMed ID: 25976681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate nephropathy: A case series and review of the literature.
    de Roij van Zuijdewijn C; van Dorp W; Florquin S; Roelofs J; Verburgh K
    Br J Clin Pharmacol; 2021 Sep; 87(9):3485-3491. PubMed ID: 33595131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate treatment recommendations for oncologists.
    von Moos R
    Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity related to new therapeutic compounds.
    Szeto CC; Chow KM
    Ren Fail; 2005; 27(3):329-33. PubMed ID: 15957551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
    Merigo E; Manfredi M; Meleti M; Corradi D; Vescovi P
    J Oral Pathol Med; 2005 Nov; 34(10):613-7. PubMed ID: 16202082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.